Goldman Sachs analyst Corinne Johnson resumed coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $97 price target The firm is positive on the size of the hypothalamic obesity market and estimate a peak sales opportunity for Rhythm at $1.9B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Reports Positive Phase 2 Trial Results
- Rhythm Pharmaceuticals price target raised to $102 from $88 at Leerink
- Rhythm Pharmaceuticals announces $150M common stock offering
- Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham
- Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA